T-cell Receptors Specific for Both Rac1- and Rac2-Derived Mutated Epitopes

Simple SummaryContent extracted from patent full text and abstract with AI.

This invention provides engineered T-cell receptors (TCRs) that specifically recognize neo-epitopes derived from mutated RAC1 (P29S) and RAC2 (P29L) proteins, which are associated with various cancers. These TCRs and their genetic constructs can be introduced into host cells, particularly T-cells, to create targeted cellular immunotherapies. The TCRs exhibit high specificity and cross-reactivity to both RAC1 and RAC2 neo-epitopes, enabling the immune system to effectively target and destroy cancer cells presenting these mutations. Applications also include pharmaceutical compositions and diagnostic methods using these TCRs or derived materials.

Use CasesContent extracted from patent full text and abstract with AI.

• Adoptive T-cell therapy for cancers expressing mutated RAC1 or RAC2 proteins (e.g., melanoma, breast cancer, head and neck cancer).
• Development of autologous or allogeneic T-cell therapies targeting RAC1/RAC2 mutant tumors.
• Diagnostic assays for detecting RAC1 P29S and RAC2 P29L mutations in patient samples.
• Customized immunotherapies for patients whose tumors express P29S or P29L RAC mutations.
• Use in research to study immune responses to RAC mutants in cancer models.

BenefitsContent extracted from patent full text and abstract with AI.

• Enables targeted immunotherapies for difficult-to-treat and metastatic cancers associated with RAC1/RAC2 mutations.
• High selectivity and cross-reactivity for relevant neo-antigens improve treatment coverage among patients.
• Reduces off-target effects and toxicity due to improved recognition specificity.
• Potential to expand immunotherapy options beyond conventional CAR-T and standard TCR therapies.
• Facilitates the development of both therapeutic and diagnostic products for precision oncology.
• Allows generation and use of both human-derived and engineered TCR constructs, increasing flexibility and compatibility.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The invention is based on antigen binding proteins (ABPs) such as T-cell receptors (TCR) expressed on T-cells, which have a specificity to bind to MHC presented Rac2 and Rac1 derived neo-epitopes, hence such MHC presented peptides derived from mutated versions of Rac1 and Rac2, such as preferably RAC2P29L and/or RAC1P29S. Provided are isolated ABPs as well as genetic constructs expressing the ABPs, recombinant host cells harboring the ABP of the invention and methods for producing such ABPs and host cells. Moreover, provided are medical applications involving the TCR of the invention, for example in context of an adoptive T-cell therapy.